[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,798,109
  • Shares Outstanding, K 58,040
  • Annual Sales, $ 718,950 K
  • Annual Income, $ -38,550 K
  • EBIT $ 35 M
  • EBITDA $ 125 M
  • 60-Month Beta 0.57
  • Price/Sales 3.99
  • Price/Cash Flow 12.77
  • Price/Book 2.60

Options Overview Details

View History
  • Implied Volatility 43.13% (-4.40%)
  • Historical Volatility 34.12%
  • IV Percentile 32%
  • IV Rank 44.85%
  • IV High 66.99% on 09/26/25
  • IV Low 23.73% on 06/11/25
  • Expected Move (DTE 23) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 54
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 3.04
  • Today's Open Interest 1,628
  • Open Int (30-Day) 1,696
  • Expected Range 47.69 to 47.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.34
  • Number of Estimates 1
  • High Estimate $0.34
  • Low Estimate $0.34
  • Prior Year $0.78
  • Growth Rate Est. (year over year) -56.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.87 +1.66%
on 05/06/26
52.96 -10.03%
on 05/06/26
-2.11 (-4.24%)
since 04/24/26
3-Month
46.83 +1.75%
on 03/20/26
56.59 -15.80%
on 02/27/26
-8.10 (-14.53%)
since 02/26/26
52-Week
30.83 +54.56%
on 06/25/25
59.68 -20.16%
on 02/25/26
+15.55 (+48.44%)
since 05/23/25

Most Recent Stories

More News
3 Stocks Under $50 with Open Questions

3 Stocks Under $50 with Open Questions

SUPN : 47.67 (-1.12%)
WASH : 32.15 (+0.19%)
IART : 14.88 (-1.46%)
3 Small-Cap Stocks That Concern Us

3 Small-Cap Stocks That Concern Us

SOUN : 8.29 (+1.47%)
SUPN : 47.67 (-1.12%)
OCSL : 11.83 (+0.51%)
3 Growth Stocks We Approach with Caution

3 Growth Stocks We Approach with Caution

SUPN : 47.67 (-1.12%)
BSM : 13.63 (-1.37%)
RGA : 212.47 (-0.73%)
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call

5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call

SUPN : 47.67 (-1.12%)
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today

Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today

SUPN : 47.67 (-1.12%)
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central...

SUPN : 47.67 (-1.12%)
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges

SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges

SUPN : 47.67 (-1.12%)
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges

1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges

SUPN : 47.67 (-1.12%)
ELV : 386.69 (-2.03%)
BMY : 58.45 (-1.70%)
Supernus: Q1 Earnings Snapshot

Supernus: Q1 Earnings Snapshot

SUPN : 47.67 (-1.12%)
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates

SUPN : 47.67 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

3rd Resistance Point 50.96
2nd Resistance Point 50.40
1st Resistance Point 49.30
Last Price 47.67
1st Support Level 47.64
2nd Support Level 47.08
3rd Support Level 45.98

See More

52-Week High 59.68
Fibonacci 61.8% 48.66
Last Price 47.67
Fibonacci 50% 45.26
Fibonacci 38.2% 41.85
52-Week Low 30.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.